Most people who have put serious money into venture capital have a story. A company that looked inevitable at the Series A and was out of business by year three. A fund that returned 0.4x after seven years of waiting and a founder who pivoted the product four times and never found the market. The upside in VC is real, but so is the reality that most of the portfolio goes to zero and the winners have to be enormous to save the fund.
There's a category of private investment that produces consistent cash flow from day one, carries downside protection that venture never offers, is backed by demographic demand that does not move with the economy, and has been systematically ignored by individual and family office investors because the deal flow never reaches them.
Ophthalmology practice acquisitions are that category, and almost nobody outside of large PE platforms knows it exists.
What Makes a Medical Practice Different From Other Private Assets
The first thing a sophisticated investor notices about a cash-flowing medical practice is that the revenue behaves differently from most private businesses which means the demand is demographic, not discretionary.
The patient population that needs cataract surgery, glaucoma monitoring, or refractive procedures is responding to biology, not making a lifestyle choice. An aging population produces predictable, recurring demand for eye care services regardless of what the economy is doing. When consumer spending contracts, elective purchases slow. Eye care visits do not follow the same curve because most of them are not elective in any meaningful sense. A 70-year-old with advancing cataracts is not postponing surgery because consumer confidence dropped.
The market is also locally captive in a way that retail and service businesses are not. A patient who has been seeing the same ophthalmologist for fifteen years is not comparison shopping. The referral relationships that feed a practice, the optometrists and primary care physicians who send patients consistently, took years to build and don't migrate easily. Acquiring a practice with an established referral network means acquiring something that a competitor opening down the street cannot replicate quickly.
The barriers to entry are structural and permanent. An ophthalmologist takes 13 years to train from undergraduate through fellowship and the supply of new practitioners is constrained by residency slots that have grown at roughly one to 2% annually for a decade. You cannot solve a physician shortage by building more clinics. The asset carries an intrinsic scarcity that most business categories simply don't have.
Why the Succession Wave Is a Deal Flow Story
The standard framing of the ophthalmology workforce gap is a healthcare crisis. 30% supply-demand mismatch by 2035, second worst staffed specialty in the country and thousands of practices without succession plans.
For a capital allocator, that same data tells a different story.
More than 5,700 solo ophthalmologists in the United States are 55 or older with no succession plan in place. By 2030, an estimated 4,300 solo practitioners will have exited practice nationally. Most of these practices are generating strong revenue, carry established patient panels, and have been operating continuously for 15-25 years. They're closing or transitioning because the founder has no one to hand them to, not because the economics have deteriorated.
The structural gap between the number of practices that need a transition and the number of qualified buyers who want to own them is what creates the acquisition opportunity. Practices are priced based on what the seller can realistically achieve in a thin buyer market, not on what the underlying cash flow would justify in a more liquid transaction environment. For an acquirer with capital, operational infrastructure, and a physician pipeline, that gap is the margin of safety.
The business works on the day you buy it and the acquirer's job is to make sure it keeps working.
The Return Profile
The return characteristics of a well-structured ophthalmology practice acquisition look different from what most private investors are used to seeing.
The cash flow is immediate. A practice doing $2 million in annual revenue on the day of close is still doing $2 million in annual revenue on the day after close. There's no ramp period, product development cycle, or customer acquisition phase. The revenue exists because the patients are there, and the patients are there because they've been coming to that office for years.
The downside protection is structural. A promissory note with defined repayment terms and structural downside protection means the investor's capital has a defined repayment path independent of the equity upside. A practice with $450,000 in annual net cash flow covers a $70,000 annual note service at 6x (DSCR) coverage. That coverage ratio puts it in a category closer to infrastructure debt than to venture, with real cash flow backing a real obligation.
The equity upside comes from operational improvement and platform expansion. A practice acquired at 0.65x revenue with room to expand subspecialty services, optimize billing, and grow the patient panel has meaningful upside that compounds over time without requiring a forced exit or a strategic buyer. Permanent hold vehicles in healthcare services produce returns that PE fund structures systematically undervalue because PE is optimizing for a 5 year exit, not for the compounding value of a practice that keeps generating cash for twenty years.
Most individual allocators are deploying private capital into VC funds where 70% of portfolio companies return nothing, real estate where cap rates have compressed to the point where leverage is doing most of the work, or angel investments in pre-revenue companies where the timeline to liquidity is measured in decades if it comes at all. A cash-flowing medical practice with 6x DSCR, structured downside protection, and a demographic tailwind is a fundamentally different risk category. It just hasn't been presented to most individual investors because the deal flow lives inside relationships, not on platforms.
Why Most Investors Never See These Deals
The ophthalmology acquisition market has been dominated by large PE platforms precisely because individual and family office investors have no efficient way to access it. PE groups have the deal sourcing infrastructure, operational teams, and capital to acquire practices at scale. Individual investors don't have those things, so they have never participated.
What changes the access equation is an operator with the sourcing capability, physician relationships, and operational infrastructure to acquire practices that PE considers too small to bother with. Solo practices below the threshold where large platforms allocate attention are not below the threshold where the underlying economics make sense.
The sub-$5 million practice acquisition market has produced consistent returns for operators who know how to run it and has been systematically overlooked by everyone else because the deal size does not justify a PE fund's overhead. That is exactly where the most attractive acquisition multiples live, the competition is thinnest, and the demographic momentum is strongest.
Why This Is Not a Rollup
The PE rollup model in healthcare acquires at scale, standardizes aggressively, and exits to a strategic buyer at a higher multiple. The returns depend on the exit, and when the exit doesn't come or comes at the wrong price, everyone downstream absorbs the cost. A permanent hold structure with no exit dependency keeps the incentives between operator and investor aligned over the long term rather than optimizing for a 3-5 year window. The distinction between those two models matters enough that we wrote a full piece on it.
The Opportunity Window
The succession wave producing this deal flow is not permanent. Over the next decade, the densest cohort of retiring solo ophthalmologists will transition out of practice. The practices that don't find a structured acquirer face 3 outcomes: consolidation into larger groups at unfavorable terms, absorption by PE at prices that reflect distress rather than value, or closure.
The third outcome is the one nobody talks about. A practice that took 25 years to build closes its doors, patients scatter, staff disperse, and the entire value of that business disappears because nobody showed up with a transition plan before the physician ran out of time.
The acquisition opportunity is most attractive now, while the supply of transitioning practices exceeds the supply of credible acquirers and before the most valuable practices have already been absorbed or lost entirely. Capital that enters this market in the next 3-5 years enters at the most favorable point in the cycle.
Capital that waits for the market to become obvious enters after the pricing has adjusted and the best deals are gone. If this asset class is new to you and you want to understand how it works, we're open to the conversation.
This article is for general educational purposes and is not investment advice.
Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you are evaluating private healthcare investments and want to understand the mechanics of this market, we are open to thoughtful conversations.
Contact info@verdira.com | 307-381-3734 | verdira.com
